Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | QPCT | Q16769 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3735188 | 0.68 | — | — | |
| SCHEMBL3737737 | 0.68 | — | — | |
| SCHEMBL6077012 | 0.67 | LMNA (0.36) | — | |
| SCHEMBL23139103 | 0.65 | CYP19A1 (0.42) | CYP19A1CYP11B1CYP11B2QPCT | |
| SCHEMBL6076784 | 0.64 | APAF1 (0.39) | — | |
| SCHEMBL21785263 | 0.62 | — | — | |
| SCHEMBL20702894 | 0.61 | CYP1A2 (0.39) | CYP19A1CYP11B1CYP11B2QPCT | |
| SCHEMBL9602863 | 0.61 | CYP3A4 (0.40) | CYP19A1 | |
| SCHEMBL9092789 | 0.61 | HTR7 (0.43) | — | |
| SCHEMBL3978875 | 0.61 | CYP11B1 (0.38) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280042-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | HENNEQUIN LAURENT FRANCOIS ANDRE | 2010-11-04 | — | — | US | disclosed |
| EP-1453492-B1 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2007-01-24 | — | — | EP | disclosed |
| US-7160891-B2 | Quinazoline derivatives for the treatment of T cell mediated diseases | ASTRAZENECA AB (SE) | 2007-01-09 | — | — | US | disclosed |
| US-7157467-B2 | Administering compound such as 6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-morpholinopropoxy)quinazoline for therapy of an autoimmune disease or medical condition selected from transplant rejection and rheumatoid arthritis | ASTRAZENECA AB (SE) | 2007-01-02 | — | — | US | disclosed |
| US-7115615-B2 | Quinazoline derivatives | ASTRAZENECA (SE) | 2006-10-03 | — | — | US | disclosed |
| US-7049438-B2 | Quinazoline derivatives for treatment of tumours | ASTRAZENECA AB (SE) | 2006-05-23 | — | — | US | disclosed |
| EP-1450808-B1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| US-20050038050-A1 | Quinazoline derivatives for the treatment of t cell mediated diseases | ASTRAZENECA AB (SE) | 2005-02-17 | — | — | US | disclosed |
| US-20050014773-A1 | Therapeutic use | ASTRAZENACA AB (SE) | 2005-01-20 | — | — | US | disclosed |
| US-20040214841-A1 | Quinazoline derivatives for treatment of tumours | ASTRAZENECA AB (SE) | 2004-10-28 | — | — | US | disclosed |
| US-20040034046-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014773-A1 | Therapeutic use | CD4, HLA-DRB1, CD74 | CYP19A1 2588/4885CYP11B1 716/4885CYP11B2 712/4885 |
| US-20040214841-A1 | Quinazoline derivatives for treatment of tumours | NQO2, TOP1, TPD52L2 | CYP19A1 1425/4885CYP11B1 1113/4885CYP11B2 678/4885 |
| US-20050038050-A1 | Quinazoline derivatives for the treatment of t cell mediated diseases | CD4, HLA-DRB1, IFNG | CYP19A1 2376/4885CYP11B1 1210/4885CYP11B2 806/4885 |
| US-20100280042-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | TPD52L2, NQO2, H1-5 | CYP19A1 833/4885CYP11B1 878/4885CYP11B2 478/4885 |
| US-20040034046-A1 | Quinazoline derivatives | NQO2, NRAS, TOP1 | CYP19A1 1216/4885CYP11B1 608/4885CYP11B2 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.